Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging
Methods, compositions, systems, devices and kits are provided herein for preparing and using a nanoparticle composition and spatial frequency heterodyne imaging for visualizing cells or tissues. In various embodiments, the nanoparticle composition includes at least one of: a nanoparticle, a polymer layer, and a binding agent, such that the polymer layer coats the nanoparticle and is for example a polyethylene glycol, a polyelectrolyte, an anionic polymer, or a cationic polymer, and such that the binding agent that specifically binds the cells or the tissue. Methods, compositions, systems, devices and kits are provided for identifying potential therapeutic agents in a model using the nanoparticle composition and spatial frequency heterodyne imaging.
1. A method of imaging cells or a target tissue in a sample, the method comprising:
contacting the cells or the target tissue with a nanoparticle composition comprising nanoparticles that bind to or are phagocytosed by the cells or the target tissue, irradiating the sample with an X-ray beam, and
imaging the cells or tissue by X-ray scatter imaging such that presence of the nanoparticles in nanoparticle-bearing cells or the target tissue improves image clarity, sensitivity and visibility of the cells or target tissue effectively enabling in situ detection of a tumor a few millimeters in size in the x-ray scatter image of an organ or tissue.
2. The method according to claim 1 , further comprising prior to contacting the nanoparticle composition, constructing the nanoparticles with at least one material selected from the group consisting of: a metal, a metal oxide, and an organic material.
3. The method according to claim 1 , further comprising prior to contacting, constructing the nanoparticles with a magnetic resonance imaging agent thereby enabling MRI imaging of the target tissue imaged by X-ray scatter imaging.
4. The method according to claim 1 , wherein the nanoparticles include a polymer layer that comprises at least one of: a polyethylene glycol, a polyelectrolyte, an anionic polymer, and a cationic polymer.
5. The method according to claim 1 , further comprising prior to contacting, constructing the nanoparticle with at least one metal selected from the group consisting of: silver, copper, gold, cadmium, zinc, nickel, palladium, platinum, rhodium, platinum, manganese, gadolinium, dysprosium, tantalum, titanium, and iron.
6. The method according to 1 , wherein irradiating the sample comprises locating or inserting an absorption grid adjacent to the sample between an X-ray source and a detector.
7. The method according to claim 1 , wherein detection of the tumor is performed by spatial frequency heterodyne imaging.
8. The method according to claim 1 , wherein the nanoparticles include a binding agent selected from the group consisting of: a drug, a protein, a carbohydrate, a nucleotide sequence and a combination thereof.
9. The method according to claim 1 , wherein the tissue comprises a plurality of cells selected from the group consisting of: cancerous, non-cancerous, epithelial, hematopoietic, stem, spleen, kidney, pancreas, prostate, liver, neuron, breast, glial, muscle, sperm, heart, lung, ocular, brain, bone marrow, fetal, blood, leukocyte, lymphocyte, and a combination thereof.
10. The method according to claim 8 , wherein the protein is an antibody selected from the group consisting of: a monoclonal antibody, a polyclonal antibody, a single-chain antibody (scFv); a recombinant heavy-chain-only antibody (VHH); an Fv; a Fab; a Fab′; and a F(ab′) 2 .
11. The method according to claim 10 , wherein the monoclonal antibody specifically binds a tumor antigen selected from the group consisting of: aspartyl (asparaginyl)-β-hydroxylase, alphafetoprotein, carcinoembryonic antigen (CA), CA-125, mucin 1, epithelial tumor antigen, tyrosinase, melanoma-associated antigen, tumor protein 53, human chorionic gonadotropin, vimentin, CD34, desmin, prostate specific antigen, and glial fibrillary acidic protein.
12. The method according to claim 10 , wherein the monoclonal antibody comprises all or a functional portion thereof of FB50 antibody, or SF25 antibody.
13. The method according to claim 1 , further comprising detecting a tumor in the cells or the tissue revealed by the scatter-imaging, wherein the tumor is selected from the group consisting of: melanoma; colon carcinoma; pancreatic; lymphoma; glioma; lung; esophagus; mammary; prostate; head; neck; ovarian; stomach; kidney; liver; and hepatocellular carcinoma.
14. The method according to claim 13 , wherein the nanoparticles have been constructed to target and bind to the tumor.
15. The method according to claim 1 , wherein the nanoparticles include a core portion and a shell portion.
16. The method according to claim 15 , wherein the core and shell have different electron densities.